Aap2-M1

**Aap2-M1** is an investigational synthetic antimicrobial peptide from ContraFect developed within the company's amurin peptide program for drug-resistant **Gram-negative bacterial infections**. Publicly available information indicates it remained at the **preclinical** stage and was later **discontinued**. The peptide has been described as a **cell wall inhibitor** with antibiofilm activity, including reported ex vivo eradication of *Stenotrophomonas maltophilia* biofilm in infected hemodialysis catheter material, but specific molecular target details, formulation, and clinical pharmacology have not been clearly disclosed in accessible primary sources.

Other names

amurin peptide candidate Aap2-M1